ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of cardiovascular, bone mineral, and hematological disorders in chronic hemodialysis patients
Abstract
Aims: The prevalence of cardiovascular diseases, bone mineral disorders, and anemia in patients undergoing continuous hemodialysis is higher than in the normal population. In addition, due to the ongoing renal parenchymal loss in these patients, there is continuous deterioration in bone mineral metabolism. Anemia, a leading hematological disorder, is considered to be one of the most important and frequent complications leading to compromised quality of life. In this study, we aimed to investigate cardiovascular, bone mineral, and hematological disorders in patients undergoing continuous hemodialysis.
Methods: Clinical data of 56 patients receiving continuous hemodialysis at Yüzüncü Yıl University Faculty of Medicine Hospital Nephrology Clinic Dialysis Unit between 01.07.2021 and 01.07.2022 were evaluated retrospectively. Echocardiography), dual-energy X-Ray absorptiometry and laboratory parameters were evaluated for each patient. Demographic characteristics and medications were recorded. Due to the retrospective nature of the study, the sample size was not calculated.
Results: The study included 56 patients undergoing hemodialysis, comprising 26 (46.4%) men and 30 (53.6%) women. Mean duration of hemodialysis was 5.55±5.09 years. Moreover, 92.9% of the patients were receiving medications, with the most common medications including erythropoiesis-stimulating agents (69.6%), phosphorus binders (48.2%), iron supplements (28.6%), active vitamin D supplements (37.5%), and cinacalcet (12.5%). Cardiovascular diseases were detected in 60.7% of the patients, osteoporosis in 41.1%, and anemia in 78.6%.
Conclusion: Cardiovascular disease, bone mineral disorders, and hematological disorders are commonly seen in hemodialysis patients. Hemodialysis patients should be regularly evaluated for complications.

Keywords : Hemodialysis, cardiovascular diseases, osteoporosis, anemia, erythropoiesis-stimulating agent

Download Article


1. Andrassy KM. Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84(3):622-623. doi:10.1038/ki.2013.243
2. Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59. 2017;7(3):e1. doi:10.1016/j.kisu.2017.10.001
3. Murat BD, Sürücüoğlu MS. Kalp, böbrek, diyabet ilişkili yeni bir tanım: “kardiyovasküler böbrek metabolik sendromu”nun incelenmesi. Beslenme Diyet Derg. 2024;52(3):61-69. doi:10.33076/2024.BDD.1860
4. Bakanlığı TS. Türkiye Halk Sağlığı Kurumu. Türkiye Kanser İstatistikleri. 2015.
5. Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM. Hip fracture in patients with non-dialysis-requiring chronic kidney disease. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016;31(10):1803-1809. doi:10.1002/jbmr.2862
6. Najar MS, Mir MM, Muzamil M. Prevalence of osteoporosis in patients with chronic kidney disease (stages 3-5) in comparison with age- and sex-matched controls: a study from Kashmir Valley Tertiary Care Center. Saudi J Kidney Dis Transpl. 2017;28(3):538-544. doi:10.4103/1319-2442.206439
7. Festuccia F, Jafari MT, Moioli A, et al. Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2017;30(2):271-279. doi:10.1007/s40620-016-0334-1
8. Aslan B, Sarı F. Hemodiyaliz ve periton diyalizi yapan hastalarda osteoporoz sıklığı ve osteoporoz gelişmesini etkileyen faktörler. Akdeniz Tıp Derg. 2021;7(2):277-282.
9. Caner B, Toprak Ö. Kronik böbrek hastalığı varlığında hastanede edinilmiş anemi gelişimine etki eden faktörlerin değerlendirilmesi. Sağl Bil Derg. 2023;32(3):394-398. doi:10.34108/eujhs.1200354
10. Altun E. Hemodiyaliz tedavisine devam eden hastalarda cilt lezyonlarının sıklığı ve ilişkili faktörler: tek merkez deneyimi. Kahramanmaraş Sütçü İmam Üniv Tıp Fak Derg. 2022;17(2):134-139. doi:10.17517/ksutfd.109674
11. Ağar BE, Kara A, Uzun F, Genç E, Gürgöze MK. Kronik böbrek hastalığı tanısı ile takipli hastaların klinik ve etiyolojik değerlendirmesi: tek merkez deneyimi. Firat Tip Derg. 2023;28(4):300-304.
12. Süleymanlar G, Utaş C, Arinsoy T, et al. A population-based survey of chronic renal disease in Turkey-the CREDIT study. Nephrol Dial Transplant. 2011;26(6):1862-1871. doi:10.1093/ndt/gfq656
13. Aktürk S. Eritropoetin tedavisi alan kronik hemodiyaliz hastalarında hekim bazlı tedavi yönetimiyle yazılım (nefroliz) destekli tedavi yönetiminin hemoglobin dalgalanması üzerine etkilerinin karşılaştırılması (Doctoral dissertation, Dokuz Eylül Universitesi, Turkiye). 2011.
14. Seyahi N, Ateş K, Süleymanlar G. Current status of renal replacement therapies in Turkey: Turkish Society of Nephrology Registry 2014 Summary Report. Turk Neph Dial Transpl. 2016;25(2):133-139. doi:10.5262/tndt.2016.1002.02 </ol> <p>
Article available in :
Volume 3, Issue 4, 2025
Page : 77-81
https://doi.org/10.51271/ICJIM-0063
Article Information
Received : 06 Ağu 2025
Accepted : 17 Eki 2025
Published : 26 Eki 2025
Corresponding Author :

Ozan Aydemir: Department of Internal Medicine, Faculty of Medicine, Yüzüncü Yıl University, Van, Turkiye

[email protected]
Citation : Özgül B, Aydemir O, Erdem M, Eliş E, Ebinç S. Evaluation of cardiovascular, bone mineral, and hematological disorders in chronic hemodialysis patients. Intercont J Int Med. 2025;3(4):77-81.

Read: 52
Download : 31
Cited: 0
_Footer